---
layout: use-case-detail
title: "References — Autonomous Adverse Event Report Processing in Pharmacovigilance"
uc_id: "UC-500"
uc_title: "Autonomous Adverse Event Report Processing in Pharmacovigilance"
detail_type: "references"
detail_title: "References"
category: "Industry-Specific"
category_icon: "briefcase"
industry: "Pharmaceutical / Life Sciences"
complexity: "High"
status: "detailed"
slug: "UC-500-pharma-adverse-event-processing"
permalink: /use-cases/UC-500-pharma-adverse-event-processing/references/
---

## Source Quality Notes

The evidence base combines production deployment announcements from major PV technology vendors (ArisGlobal, IQVIA, Tech Mahindra) with a peer-reviewed feasibility study (Pfizer/PMC) and regulatory standards documentation (ICH, FDA). Vendor metrics (S1, S3, S4) come from press releases and product pages — they report favorable results but lack independent audit detail. The Pfizer study (S2) is peer-reviewed but dates from 2019 and uses pre-LLM ML models, meaning its F1 baselines are conservative for current-generation systems. The regulatory sources (S5, S6, S7) are authoritative primary documents. The IQVIA article (S4) reports internal targets, not independently verified production metrics. Overall, the evidence strongly supports feasibility and direction-of-travel economics, but precise ROI figures should be treated as vendor-reported estimates rather than audited benchmarks.

## Source Register

| ID | Type | Source | Why It Was Used | Link |
|----|------|--------|-----------------|------|
| S1 | Vendor deployment | ArisGlobal — NavaX Translation Launch Press Release (February 2026) | Production volume (1M+ cases), accuracy (>95%), efficiency gains (>30%), adoption by 6 top-25 pharma companies | [PR Newswire](https://www.prnewswire.com/apac/news-releases/arisglobal-launches-navax-translation-to-eliminate-manual-translation-in-global-pharmacovigilance-302698489.html) |
| S2 | Peer-reviewed study | Schmider et al. — "Innovation in Pharmacovigilance: Use of Artificial Intelligence in Adverse Event Case Processing" (Clinical Pharmacology & Therapeutics, 2019) | Baseline F1 scores (0.52–0.74) for ICSR extraction; 81% case validity classification; methodology for evaluating AI in PV | [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC6590385/) |
| S3 | Vendor deployment | Tech Mahindra — PV Agentic LLM product page and NVIDIA collaboration press release (March 2025) | 60% manual effort reduction, 45% case prioritization improvement, 40% turnaround reduction, agentic architecture description | [Tech Mahindra PV Agentic LLM](https://www.techmahindra.com/industries/healthcare-life-sciences/pharmacovigilance-agentic-llm/) |
| S4 | Vendor deployment | IQVIA — Vigilance Detect fact sheet and Drug Discovery Trends interview (2024–2025) | 80% fewer false positives, 50% cost reduction target with >99% quality goal, modular platform architecture | [IQVIA Fact Sheet](https://www.iqvia.com/library/fact-sheets/iqvia-vigilance-detect-transforming-pharmacovigilance-with-measurable-outcomes) |
| S5 | Domain standard | ICH — E2B(R3) Individual Case Safety Report Specification | Defines the mandatory data elements, message structure, and XML schema for electronic ICSR submission globally | [ICH E2B(R3)](https://ich.org/page/e2br3-individual-case-safety-report-icsr-specification-and-related-files) |
| S6 | Regulatory guidance | FDA — "Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products" (Draft Guidance, January 2025) | Risk-based credibility framework for AI in drug lifecycle; pharmacovigilance-specific guidance acknowledged as needed | [FDA Guidance](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological) |
| S7 | Official data | FDA — Adverse Event Reporting System (FAERS) | Database statistics supporting volume claims (~700K reports/year, 21M+ total entries) | [FDA FAERS](https://www.fda.gov/drugs/surveillance/fdas-adverse-event-reporting-system-faers) |
| S8 | Vendor deployment | Tech Mahindra and NVIDIA collaboration press release (March 19, 2025) | Specific metrics: 40% turnaround reduction, 30% accuracy enhancement, 25% cost decrease; 1,000+ daily ADR cases as industry benchmark | [PR Newswire](https://www.prnewswire.com/news-releases/tech-mahindra-and-nvidia-collaborate-to-advance-drug-safety-with-agentic-ai-powered-pharmacovigilance-solution-302405792.html) |
| S9 | Industry analysis | Drug Discovery Trends — "IQVIA's AI Vision Is to Cut Pharmacovigilance Costs by 50% with Superhuman Accuracy" (2024) | IQVIA's stated targets, current module status, human accuracy baseline (~90%), and deployment timeline context | [Drug Discovery Trends](https://www.drugdiscoverytrends.com/iqvias-ai-vision-is-to-cut-pharmacovigilance-costs-by-50-with-superhuman-accuracy/) |

## Claim Map

| Claim Or Section | Source IDs |
|------------------|------------|
| >95% data accuracy achievable at production scale (1M+ cases) | S1 |
| ICSR field extraction F1 of 0.52–0.74 as early ML baseline; 81% case validity | S2 |
| 60% manual effort reduction with agentic LLM architecture | S3 |
| 80% fewer false positives in adverse event detection; 50% cost reduction target | S4, S9 |
| Human manual accuracy baseline ~90% (1 in 10 cases requires correction) | S9 |
| ICH E2B(R3) as mandatory submission format (FDA mandatory April 2026) | S5 |
| FDA risk-based credibility framework for AI in drug lifecycle | S6 |
| ~700,000 AE reports/year in US; 21M+ total FAERS entries | S7 |
| 40% turnaround reduction, 1,000+ daily ADR cases industry benchmark | S8 |
| 2–4 hours per routine ICSR, $686K/year per product PV cost | S2, S3, S4 |
| Tiered autonomy model (non-serious autonomous, serious human-reviewed) | S1, S3, S4 |
| MedDRA coding requires retrieval-augmented approach due to biannual updates | S2, S5 |
| Regulatory landscape: FDA draft guidance acknowledges AI but lacks PV-specific validation requirements | S6 |
